Sidney Pitts

Sidney Pitts

Auto-generated profile, based on publicly available information

Sidney Pitts

Department of Pathology Morehouse School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
WSWesley Solomon
Wesley Solomon
NWNana O Wilson
Nana O Wilson
LALeonard Anderson
Leonard Anderson
SPSidney Pitts
Sidney Pitts
JPJohn Patrickson
John Patrickson
JSJonathan Kwamina Stiles
Jonathan Kwamina Stiles
Cerebral Malaria (CM) is a diffuse encephalopathy caused by Plasmodium falciparum infection. Despite availability of antimalarial drugs, CM-associated mortality remains high at approximately 30% and a subset of survivors develop neurological and cognitive disabilities. While antimalarials are effective at clearing Plasmodium parasites they do little to protect against CM pathophysiology and parasite-induced brain inflammation that leads to seizures, coma and long-term neurological sequelae in CM patients. Thus, there is urgent need to explore therapeutics that can reduce or prevent CM pathogenesis and associated brain inflammation to improve survival. Neuregulin-1 (NRG-1) is a neurotrophic growth factor shown to protect against brain injury associated with acute ischemic stroke (AIS) and neurotoxin exposure. However, this drug has not been tested against CM-associated brain injury. Since CM-associated brain injuries and AIS share similar pathophysiological features, we hypothesized that NRG-1 will reduce or prevent neuroinflammation and brain damage as well as improve survival in mice with late-stage experimental cerebral malaria (ECM).